DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/248dc5/sweden_pharmaceuti) has announced the addition of the "Sweden Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
International's Sweden Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Sweden's pharmaceuticals and healthcare industry.
BMI View: While there is a demand for high-value innovative drugs in Sweden, as highlighted by company and product sales, the forecast period is likely to feature the proliferation of government initiatives supporting the growth of the generic medicines market. Such cost containment initiatives in the healthcare sector should attract prominent international generic players in the field, as well as prompting local companies to get more involved in the segment.
Headline Expenditure Projections
- Pharmaceuticals: SEK30.57bn (US$3.85bn) in 2010 to SEK31.32bn (US$4.06bn) in 2011; - 0.8% in local currency terms and +5.6% in US dollar terms.
- Healthcare: SEK323.84bn (US$40.75bn) in 2010 to SEK337.06bn (US$45.17bn) in 2011; +4.1% in local currency terms and +10.8% in US dollar terms.
- Medical devices: SEK18.51bn (US$2.42bn) in 2010 to SEK19.28bn (US$2.43bn) in 2011; +4.2% in local currency terms and +0.2% in US dollar terms.
Business Environment Rating: In BMI's Pharmaceuticals Business Environment Ratings for Q411, Sweden remains the seventh most attractive market of the Western European countries surveyed, scoring 61.6 out of 100, which is below the regional average. While the country's strong emphasis on the regulatory environment is a draw, a major factor affecting the business environment for drugmakers is its small overall market size, which - combined with pressure on pharmaceutical spending - negatively affects the Industry Rewards score in particular. Nevertheless, given its high per capita drug expenditure level, medicines continue to bring in substantial income for companies operating in Sweden.
Companies Mentioned:
- Meda
- Swedish Orphan Biovitrum
For more information visit http://www.researchandmarkets.com/research/248dc5/sweden_pharmaceuti